Similar articles

• Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

  Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Tannir NM, et al. Eur Urol. 2016 May;69(5):866-74. doi: 10.1016/j.eururo.2015.10.049. Epub 2015 Nov 26. Eur Urol. 2016. PMID: 26626617 Free PMC article. Clinical Trial.
• Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.

  Lei Y, Yildiz S, Chen M. Lei Y, et al. Eur Urol. 2017 Sep;72(3):e72-e73. doi: 10.1016/j.eururo.2017.01.012. Epub 2017 Jan 17. Eur Urol. 2017. PMID: 28108150 No abstract available.
• Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.

  Hsieh JJ, Marker M, Chen D. Hsieh JJ, et al. Eur Urol. 2017 Sep;72(3):e74-e75. doi: 10.1016/j.eururo.2017.01.013. Epub 2017 Jan 19. Eur Urol. 2017. PMID: 28111113 No abstract available.
• Metastatic renal cell carcinoma: current standards of care.

  Thompson JA. Thompson JA. Clin J Oncol Nurs. 2009 Dec;13 Suppl:8-12. doi: 10.1188/09.CJON.S2.8-12. Clin J Oncol Nurs. 2009. PMID: 19948454 Review.
• Targeted Therapy for Metastatic Renal Cell Carcinoma.

  Afriansyah A, Hamid AR, Mochtar CA, Umbas R. Afriansyah A, et al. Acta Med Indones. 2016 Oct;48(4):335-347. Acta Med Indones. 2016. PMID: 28143997 Review.